Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humoral response to COVID-19 vaccines in Brazil
RBR-33ndb47Recruiting
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of ChAdOx1 nCoV-19, coronavac and tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Fundação Oswaldo Cruz. Started Feb 2021; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19coronavactozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-33ndb47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-33ndb47.